Russian defence ministry claims virus vaccine is tested and safe

Cheryl Sanders
July 16, 2020

The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that the adaptive phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine. "Sechenov University has successfully completed trials on the world's first vaccine volunteers against coronaviruses" said Tarasov. Experts are working day and night to do these experiments and it is their moral duty to develop vaccines as fast as possible as more than half a million people have succumbed to COVID-19 across the world.

According to TASS, Russia's largest news agency, the first stage of research on the vaccine started on June 18 when a group of 18 volunteers were vaccinated, and the second stage on June 23 with a group of 20 volunteers being vaccinated. Initially, some participants reported headaches and high body temperature.

It takes at least 14 days to test sterility, which is the first step critical to patient safety and a deciding factor on whether the vaccine candidate is safe for human dosage.


In the meantime, the volunteers have been kept in single or double wards on campus at Sechenov University. However, most countries and the World Health Organization is likely to disapprove of this claim. Also, scale of volunteers was small, hence more comprehensive research might be needed before the vaccine is cleared for use.

As the world is waiting eagerly for the Coronavirus vaccine, Russia's Sechenov University revealed that the clinical trials of the world's first vaccine against the novel Coronavirus have been completed.

The Sechenov University of Russian Federation has claimed to have successfully completed the clinical trials of the COVID-19 vaccine on humans and the results have proven the medication's effectiveness.


Scientists in Russian Federation are developing 47 potential vaccines, according to officials. Recently, Sinovac collaborated with Instituto Butantan in Brazil to prepare and conduct Phase 3 clinical study. Zydus had earlier this month announced that ZyCoV-D developed in Ahmedabad, had successfully completed the preclinical phase and received permission from Drug Controller General of India to initiate human trials.

It should be called a potential vaccine, which is still in trials and needs scientific calls. Around 800 people will be administered the vaccine.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER